Recent Updates
Recently added Catalysts
OVID Positive Sentiment

Alliance to Cure

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Alliance to Cure Cavernous Malformation is a charitable organization dedicated to supporting individuals affected by cavernous malformations. Its mission includes informing the public, providing support, and advancing research for improved treatments and a potential cure. The organization aims to mobilize the community towards these goals.
Price reaction · baseline $3.53 (2023-09-22T16:20:00.000Z) · hit during market hours · 23 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • The organization aims to support those affected by cavernous malformations.
  • It focuses on driving research for better treatments and a cure.
  • The initiative promotes community mobilization and awareness.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

The Alliance to Cure Cavernous Malformation is a non-profit, charitable organization created with the mission to inform, support, and mobilize those affected by cavernous malformations (CCM, cavernous angioma, cavernoma) and drive research for better treatments and the cure.
Visit Site »

Frequently Asked Questions

What is the mission of the Alliance to Cure?

The mission is to inform, support, and mobilize those affected by cavernous malformations.

How does the Alliance support research?

The Alliance drives research efforts for better treatments and a potential cure.

Is the Alliance a non-profit organization?

Yes, the Alliance to Cure is a non-profit, charitable organization.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare cavernous malformations CCM cavernous angioma cavernoma research
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →